The records of 19,082 patients with non-uroepithelial cancers were reviewed to determine the incidence of de novo bladder cancer in patients treated with cyclophosphamide versus patients not treated with this drug. A 9-fold increased incidence of bladder cancer was found in the cyclophosphamide-treated group.